Germline Modification Carries Risk of Major Social Harm
By Marcy Darnovsky,
Nature
| 06. 04. 2008
Your Editorial 'New sources of sex cells' (Nature 452, 913; 2008), on the potential use of pluripotent stem-cell-derived gametes (PSCDGs) for germline genetic modification and enhancement, suggests that the prospect of stem-cell-derived gametes could trigger renewed calls for regulating human biotechnologies. In those discussions we must, as you warn, be wary of impeding basic research. But we must be equally willing to draw lines proscribing socially pernicious applications.
Germline (that is, inheritable) modification is the most socially consequential and ethically dubious application of human biotechnology; its implications have been explored from a wide range of perspectives. Most of these discussions have focused on the social meaning and repercussions of genetic manipulation of the human species, not on the moral status of human embryos. One can strongly support human-embryo research and still oppose germline modification. Conversely, some opponents of abortion rights support germline modification, so long as no embryos are destroyed in the process.
Although there may be scientific and therapeutic benefits from research on PSCDGs, the case for any such benefits from using these cells for human germline modification is...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...